^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients

Excerpt:
In addition, a novel activation loop mutation, G846S (exon 20), was identified in patient 22. Patients were also genotyped for mutations in KIT, another SU11248 target….These data clearly demonstrate that a single dose of SU11248 results in inhibition of FLT3 phosphorylation in a dose-dependent manner in AML patients, with inhibition in all genotypes.
DOI:
10.1038/sj.onc.1206543